Evidence map›Paper›PMID 38366285›Full record

ReviewAnnals of clinical and translational neurology2024

Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.

Patricia K Coyle, Mark S Freedman, Bruce A Cohen, Bruce A C Cree, Clyde E Markowitz

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Observational
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Patricia K CoyleDepartment of Neurology, Stony Brook Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
Mark S FreedmanUniversity of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Bruce A CohenDepartment of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Bruce A C CreeWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0001-7689-2533
Clyde E MarkowitzDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Northwestern University · USStony Brook School · USUniversity of California, San Francisco · USUniversity of Ottawa · CAUniversity of Pennsylvania · US

Funding

Bristol Myers Squibb
6 · The paper itself

Abstract

Four sphingosine 1-phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety data on these S1P receptor modulators, with an emphasis on similarities and differences. Efficacy data from the pivotal clinical trials are generally similar for the four agents. However, because no head-to-head clinical studies were conducted, direct efficacy comparisons cannot be made. Based on the adverse event profile of S1P receptor modulators, continued and regular monitoring of patients during treatment will be instructive. Notably, the authors recommend paying attention to the cardiac monitoring guidelines for these drugs, and when indicated screening for macular edema and cutaneous malignancies before starting treatment. To obtain the best outcome, clinicians should choose the drug based on disease type, history, and concomitant medications for each patient. Real-world data should help to determine whether there are meaningful differences in efficacy or side effects between these agents.

Indexed as

Multiple SclerosisSphingosine 1 Phosphate Receptor ModulatorsAdministration, OralFingolimod HydrochlorideHumansSphingosine-1-Phosphate ReceptorsUnited StatesFingolimod HydrochlorideSphingosine 1 Phosphate Receptor ModulatorsSphingosine-1-Phosphate Receptors

Identifiers

PMID38366285
PMCPMC11021614
OpenAlexW4391898643

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.